ATLANTA, Oct. 12 /PRNewswire/ -- Image Guided Radiation Therapy (IGRT) is the next generation in radiation oncology treatment accuracy, giving clinicians the ability to image a patient at the point of treatment and make corrections to better target a tumor and avoid surrounding healthy tissue. Elekta was the first company to develop IGRT and the first to bring it to market, and remains the world leader in this next generation of treatment accuracy.
(Logo: http://www.newscom.com/cgi-bin/prnh/20020318/ELEKTALOGO )
Elekta’s IGRT solution, known as Elekta Synergy(R), is a clinically proven digital linear accelerator being used in oncology centers worldwide in the fight against cancer. Clinicians using Elekta Synergy(R) in conjunction with X-ray Volume Imaging (XVI) realize the image quality and soft tissue detail necessary to achieve optimum clinical results.
One concern that has been raised is the ability to treat patients as quickly with this advanced technology as with previous therapies. Because reconstruction of large volumetric images is almost instantaneous, Elekta’s IGRT requires only minimal changes to existing treatment practice and treatment schedules.
“Elekta Synergy(R) is part of a continuous innovation in radiation therapy that is especially relevant in Canada. Canadian healthcare places a high value on patient throughput, cost efficiency and the quality of treatment provided,” says Mark Symons, General Manager for Elekta Canada. “By improving targeting, with minimal extra overhead, Elekta Synergy(R) offers the potential to improve therapeutic ratios and reduce the number of treatment fractions.”
With more than 4,000 clinical images from 20 installations, and more than 50 systems scheduled to be installed within the next few months, Elekta’s system has proven its clinical effectiveness and is tantalizing clinicians with its future potential.
About Elekta
Elekta is an international medical-technology group, providing meaningful clinical solutions, comprehensive information systems and services for improved cancer care and management of brain disorders. All of Elekta’s solutions employ non-invasive or minimally invasive techniques and are therefore clinically effective, gentle on the patient and cost-effective.
Clinical solutions include Leksell Gamma Knife(R) for non-invasive treatment of brain disorders and Elekta Synergy(R) for image guided radiation therapy (IGRT). Following the acquisition of IMPAC Medical Systems Inc. in April 2005, the Elekta Group became the world’s largest supplier of oncology software.
Elekta’s systems and solutions are used in over 3,000 hospitals around the world to treat cancer and to manage clinical operations as well as to diagnose and treat brain disorders, including tumors, vascular malformations and functional disorders.
With approximately 1,700 employees, Elekta’s corporate headquarters is located in Stockholm, Sweden, and the company is listed on the Stockholm Stock Exchange under the ticker EKTAb.
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20020318/ELEKTALOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk, photodesk@prnewswire.comElekta Instruments, Inc.
CONTACT: Michelle Lee, PR and Advertising Manager, +1-770-670-2447, ormichelle.lee@elekta.com ; or Investors, United States: Lars Jonsteg, VPInvestor Relations North America, +46 708 78 37 35, orlars.jonsteg@elekta.com, or International: Peter Ejemyr, Group VP CorporateCommunications, +46 733 611 000, or peter.ejemyr@elekta.com , all of ElektaInstruments, Inc.
Web site: http://www.elekta.com//